The Metabolic Effects of Intermittent Fasting

Description

Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the benefits of fasting protocols are dependent on weight loss is not known. In this study, the investigators will explore the metabolic effects of fasting and evaluate whether these effects, including negative effects on bone metabolism, are independent of weight loss.

Conditions

Normal and Overweight Individuals At High-risk of Diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the benefits of fasting protocols are dependent on weight loss is not known. In this study, the investigators will explore the metabolic effects of fasting and evaluate whether these effects, including negative effects on bone metabolism, are independent of weight loss.

The Effects of Fasting on Reprogramming of Lipid Metabolism and Bone Metabolism

The Metabolic Effects of Intermittent Fasting

Condition
Normal and Overweight Individuals At High-risk of Diabetes
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Men and women, ages 25-45 years
  • 2. BMI of at least 21 kg/m2 and up to and including BMI of 29 kg/m2
  • 3. Normal thyroid function
  • 4. Regular menses (women)
  • 5. At least one first-degree relative with type 2 diabetes (T2D) and/or history of gestational diabetes
  • 1. Any chronic diseases including hypertension and Type 2 diabetes mellitus
  • 2. Indication for lipid-lowering therapy in non-diabetics, using the more stringent AHA guideline cutoff (LDL\>190 or an estimated 10-year ASCVD risk of \>7.5%)
  • 3. Chronic medications, including oral contraceptive pills
  • 4. Pregnant and/or breastfeeding
  • 5. History of an eating disorder
  • 6. 25-OH vitamin D level \< 20 ng/mL
  • 7. Active substance abuse, including alcohol
  • 8. Subjects with a prior history of intermittent fasting
  • 9. The study physician feels that the subject may not be able to safely complete the protocol or may place themselves at risk by undergoing the protocol

Ages Eligible for Study

25 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Pittsburgh,

Pouneh Fazeli, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2028-06